Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex

Journal of Alzheimer's Disease

Volumn 28, Issue 2, 2012, Pages 403-422

  Wei, Zelan ^a   Gabriel, Geraldine G ^a   Rui, Lewei ^a   Cao, Xia ^a   Pennington, Paul R ^a   Chlan Fourney, Jennifer ^b   Nazarali, Adil J ^b   Baker, Glen B ^c   Mousseau, Darrell D ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Alzheimer's disease; depression; mitochondria; monoamine oxidase; secretase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CLORGYLINE; DOPAMINE; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CEREBELLUM CORTEX; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

EID: 84857016371     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111241     Document Type: Article

References (115)

1. Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113, 1237-1264.
2. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122, 509-522.
3. Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neu-rodegenerative disorders. Curr Pharm Des 16, 2799-2817.
4. Ritchie K, Lovestone S (2002) The dementias. Lancet 360, 1759-1766. (Pubitemid 35447916)
5. Caraci F, Copani A, Nicoletti F, Drago F (2010) Depression and Alzheimer's disease: Neurobiological links and common pharmacological targets. Eur J Pharmacol 626, 64-71.
6. Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM (2008) History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70, 1258-1264. (Pubitemid 351520949)
7. Wuwongse S, Chang RC, Law AC (2010) The putative neu-rodegenerative links between depression and Alzheimer's disease. Prog Neurobiol 91, 362-375.
8. Kessing LV, Andersen PK (2004) Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder andin patients with bipolar disorder? J Neurol Neurosurg Psychiatry 75, 1662-1666. (Pubitemid 39611460)
9. Du L, Faludi G, Palkovits M, Sotonyi P, Bakish D, Hrdina PD (2002) High activity-related allele ofMAO-A gene associated with depressed suicide in males. Neuroreport 13, 1195-1198. (Pubitemid 34722052)
10. Nishimura AL, Guindalini C, Oliveira JR, Nitrini R, Bahia VS, de Brito-Marques PR, Otto PA, Zatz M (2005) Monoamine oxidase a polymorphism in Brazilian patients: Risk factor for late-onset Alzheimer's disease? J Mol Neu-rosci 27, 213-217. (Pubitemid 41356402)
11. Takehashi M, Tanaka S, Masliah E, Ueda K (2002) Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant. Neurosci Lett 327, 79-82. (Pubitemid 34722412)
12. Wu YH, Fischer DF, SwaabDF (2007)Apromoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients. Brain Res 1167, 13-19. (Pubitemid 47302436)
13. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Williams EA, Zahm DS (2004) Neurotoxicity of MAO metabolites of cat-echolamine neurotransmitters: Role in neurodegenerative diseases. Neurotoxicology 25, 101-115. (Pubitemid 38044173)
14. Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 28, 327-335. (Pubitemid 46178530)
15. Marcyniuk B, Mann DM, Yates PO (1986) Loss of nerve cells from locus coeruleus in Alzheimer's disease is topographically arranged. Neurosci Lett 64, 247-252. (Pubitemid 16163819)
16. Parvizi J, Van Hoesen GW, Damasio A (2001) The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol 49, 53-66. (Pubitemid 32163006)
17. Rub U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H (2000) The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol 26, 553-567. (Pubitemid 32049855)
18. Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, Folstein MF, Price DL (1988) The neu-ropathologyofaminergic nuclei in Alzheimer's disease. Ann Neurol 24, 233-242.
19. Kennedy BP, Ziegler MG, Alford M, Hansen LA, Thal LJ, Masliah E (2003) Early and persistent alterations in pre-frontal cortex MAO A and B in Alzheimer's disease. J Neural Transm 110, 789-801. (Pubitemid 36783232)
20. Emilsson L, Saetre P, Balciuniene J, Castensson A, Cairns N, Jazin EE (2002) Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients. Neurosci Lett 326, 56-60. (Pubitemid 34607593)
21. Sparks DL, Woeltz VM, Markesbery WR (1991) Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. Arch Neurol 48, 718-721.
22. Sherif F, Gottfries CG, Alafuzoff I, Oreland L (1992) Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 4, 227-240.
23. Chan-Palay V, Hochli M, Savaskan E, Hungerecker G (1993) Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of meynert in senile dementia of the Alzheimer type and Parkinson's disease. Dementia 4, 1-15. (Pubitemid 23071252)
24. Burke WJ, Li SW, Schmitt CA, Xia P, Chung HD, Gillespie KN (1999) Accumulation of 3, 4-dihydroxy-phenylglycolaldehyde, the neurotoxic monoamine oxidase A metaboliteofnorepinephrine, inlocus ceruleus cell bodies in Alzheimer's disease: Mechanism of neuron death. Brain Res 816, 633-637. (Pubitemid 29225414)
25. Nazarali AJ, Reynolds GP (1992) Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: A postmortem study. Cell Mol Neurobiol 12, 581-587.
26. Gundlah C, Lu NZ, Bethea CL (2002) Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psy-chopharmacology (Berl) 160, 271-282. (Pubitemid 34230679)
27. Holschneider DP, Kumazawa T, Chen K, Shih JC (1998) Tissue-specific effects of estrogen on monoamine oxidase A and B in the rat. Life Sci 63, 155-160. (Pubitemid 28305563)
28. Ou XM, Chen K, ShihJC (2006) Monoamine oxidaseAand repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A 103, 10923-10928.
29. Fitzgerald JC, Ufer C, Billett EE (2007) A link between monoamine oxidase-A and apoptosis in serum deprived human SH-SY5Y neuroblastoma cells. J Neural Transm 114, 807-810. (Pubitemid 46980489)
30. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28, 13805-13814.
31. Szapacs ME, Numis AL, Andrews AM (2004) Late onset loss of hippocampal 5-HT and NE is accompanied by increasesin BDNF protein expressioninmice co-expressing mutant APP and PS1. Neurobiol Dis 16, 572-580. (Pubitemid 38942990)
32. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284, 4749-4753.
33. Yankner BA, Lu T (2009) Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 284, 4755-4759.
34. Ankarcrona M, Hultenby K (2002) Presenilin-1 is located in rat mitochondria. Biochem Biophys Res Commun 295, 766-770. (Pubitemid 34756914)
35. Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J, Ankarcrona M (2004) Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem 279, 51654-51660. (Pubitemid 40017916)
36. De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, Cordell B, Moechars D, Bollen M, Fraser P, George-Hyslop PS, Van Leuven F (1997) Phosphoryla-tion, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J Biol Chem 272, 3590-3598.
37. Area-Gomez E, de Groof AJ, Boldogh I, Bird TD, Gibson GE, Koehler CM, Yu WH, Duff KE, Yaffe MP, Pon LA, Schon EA (2009) Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol 175, 1810-1816.
38. Wiedemann N, Meisinger C, Pfanner N (2009) Cell biology. Connecting organelles. Science 325, 403-404.
39. Ringman JM, Diaz-Olavarrieta C, Rodriguez Y, Chavez M, Paz F, Murrell J, Macias MA, Hill M, Kawas C (2004) Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression than their non-mutation carrying kin. J Neurol Neurosurg Psychiatry 75, 500-502. (Pubitemid 38338790)
40. Comery TA, Martone RL, Aschmies S, Atchison KP, Dia-mantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25, 8898-8902. (Pubitemid 41384457)
41. Pakaski M, Bjelik A, Hugyecz M, Kasa P, Janka Z, Kalman J (2005) Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int 47, 190-195. (Pubitemid 40848681)
42. Ash ES, Alavijeh MS, Palmer AM, Mitchelmore C, Howlett DR, Francis PT, Broadstock M, Richardson JC (2010) Neu-rochemical changes in a double transgenic mouse model of Alzheimer's disease fed a pro-oxidant diet. Neurochem Int 57, 504-511.
43. Pugh PL, Richardson JC, Bate ST, Upton N, SunterD (2007) Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res 178, 18-28.
44. Zhu X, Flint Beal M, Wang W, Perry G, Smith MA, (Eds) (2010) Mitochondria and neurodegenerative diseases. J Alzheimers Dis 20 (Suppl 2), 253-643.
45. Frisoni GB, Prestia A, Rasser PE, Bonetti M, Thompson PM (2009) In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease. J Neurol 256, 916-924.
46. Larner AJ, Ray PS, Doran M (2007) The R269H mutation in presenilin-1 presenting as late-onset autosomal dominant Alzheimer's disease. J Neurol Sci 252, 173-176. (Pubitemid 46048652)
47. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP (1999) Increased vulnerability of hippocam-pal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5, 101-106. (Pubitemid 29051006)
48. Auffret A, Gautheron V, Mattson MP, Mariani J, Rovira C (2010) Progressive age-related impairment of the late longterm potentiationinAlzheimer's disease presenilin-1 mutant knock-in mice. J Alzheimers Dis 19, 1021-1033.
49. Odero GL, Oikawa K, Glazner KA, Schapansky J, Grossman D, Thiessen JD, Motnenko A, Ge N, Martin M, Glazner GW, Albensi BC (2010) Evidence for the involvement of calbindin D28k in the presenilin 1 model of Alzheimer's disease. Neuroscience 169, 532-543.
50. Cao X, Rui L, Pennington PR, Chlan-Fourney J, Jiang Z, Wei Z, Li XM, Edmondson DE, MousseauDD (2009)Serine 209 resides within a putative p38 (MAPK) consensus motif and regulates monoamine oxidase-A activity. J Neurochem 111, 101-110.
51. Brown GD, NazaraliAJ (2010)Matrix metalloproteinase-25 hasafunctional role in mouse secondary palate development and is a downstream target of TGF-beta3. BMC Dev Bio 10, 93.
52. Cao X, Wei Z, Gabriel GG, Li X, Mousseau DD (2007) Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: Implications for Alzheimer disease-related pathology. BMC Neurosci 8, 73.
53. Wei Z, Chigurupati S, Arumugam TV, Jo DG, Li H, Chan SL (2011) Notch activation enhances the microglia-mediated inflammatory response associated with focal cerebral ischemia. Stroke 42, 2589-2594.
54. Wieckowski MR, Giorgi C, Lebiedzinska M, Duszynski J, Pinton P (2009) Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. Nat Protoc 4, 1582-1590.
55. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229, 327-336. (Pubitemid 8225714)
56. Potter WZ, Murphy DL, Wehr TA, Linnoila M, Goodwin FK (1982) Clorgyline. A new treatment for patients with refractory rapid-cycling disorder. Arch Gen Psychiatry 39, 505-510. (Pubitemid 12125541)
57. Lipper S, Murphy DL, Slater S, Buchsbaum MS (1979) Comparative behavioral effects of clorgyline and pargy-lineinman:Apreliminary evaluation. Psychopharmacology (Berl) 62, 123-128.
58. Nielsen DM, Carey GJ, Gold LH (2004) Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499, 135-146. (Pubitemid 39201220)
59. Kitanaka N, Kitanaka J, Takemura M (2005) Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum. Neuroscience 130, 295-308. (Pubitemid 40125468)
60. Mousseau DD, Greenshaw AJ (1989) Chronic effects of clomipramine and clorgyline on regional levels of brain amines and acid metabolites in rats. J Neural Transm 75, 73-79. (Pubitemid 19027072)
61. Hebert SS, Godin C, Tomiyama T, Mori H, Levesque G (2003) Dimerization of presenilin-1 in vivo: Suggestion of novel regulatory mechanisms leading to higher order complexes. Biochem Biophys Res Commun 301, 119-126. (Pubitemid 36268857)
62. Cao X, Li XM, Mousseau DD (2009) Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: Possible influence by distinct signalling pathways. Life Sci 85, 262-268.
63. Fitzgerald JC, Ufer C, De Girolamo LA, Kuhn H, Billett EE (2007) Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J Neurochem 103, 2189-2199. (Pubitemid 350173561)
64. Fowler JS, Alia-Klein N, Kriplani A, Logan J, Williams B, Zhu W, Craig IW, Telang F, Goldstein R, Volkow ND, Vaska P, Wang GJ (2007) Evidence that brain MAO A activity does not correspond to MAO A genotypein healthy male subjects. Biol Psychiatry 62, 355-358. (Pubitemid 47444275)
65. Petit-Demouliere B, Chenu F, Bourin M (2005) Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology (Berl) 177, 245-255. (Pubitemid 40137284)
66. Morohashi Y, Kan T, Tominari Y, Fuwa H, Okamura Y, Watanabe N, Sato C, Natsugari H, Fukuyama T, Iwatsubo T, Tomita T (2006) C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N- (3, 5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J Biol Chem 281, 14670-14676. (Pubitemid 43855171)
67. Yang T, Arslanova D, Gu Y, Augelli-Szafran C, Xia W (2008) Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein. Mol Brain 1, 15.
68. Hayashi T, Rizzuto R, Hajnoczky G, Su TP (2009) MAM: More than just a housekeeper. Trends Cell Biol 19, 81-88.
69. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17, 181-190. (Pubitemid 26251602)
70. Berezovska O, Lleo A, Herl LD, Frosch MP, Stern EA, Bac-skai BJ, Hyman BT (2005) Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 25, 3009-3017. (Pubitemid 40389259)
71. Nyabi O, Bentahir M, Horre K, Herreman A, Gottardi-Littell N, Van Broeckhoven C, Merchiers P, Spittaels K, Annaert W, De Strooper B (2003) Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicas-trin glycosylation but remain catalytically inactive in the absence of wild type presenilin. J Biol Chem 278, 43430-43436. (Pubitemid 37345965)
72. Kim H, Ki H, Park HS, Kim K (2005) Presenilin-1 D257A and D385A mutants fail to cleave Notch in their endopro-teolyzed forms, but only presenilin-1 D385A mutant can restore its gamma-secretase activity with the compensatory overexpression of normal C-terminal fragment. J Biol Chem 280, 22462-22472. (Pubitemid 40827902)
73. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398, 513-517.
74. Chan-Palay V (1992) Depression and senile dementia of the Alzheimer type: A role for moclobemide. Psychopharma-cology (Berl) 106 (Suppl), S137-S139.
75. Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP (2000) Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem 275, 18195-18200. (Pubitemid 30414771)
76. Kulic L, Walter J, Multhaup G, Teplow DB, Baumeister R, Romig H, Capell A, Steiner H, Haass C (2000) Separation of presenilin function in amyloid beta-peptide generation and endoproteolysis of Notch. Proc Natl Acad Sci U S A 97, 5913-5918. (Pubitemid 30367498)
77. Shen J, Kelleher RJ, 3rd (2007) The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 104, 403-409. (Pubitemid 46123039)
78. Johnsingh AA, Johnston JM, Merz G, Xu J, Kotula L, Jacob-sen JS, Tezapsidis N (2000) Altered binding of mutated presenilin with cytoskeleton-interacting proteins. FEBS Lett 465, 53-58. (Pubitemid 30012114)
79. Pennington PR, Wei Z, Rui L, Doig JA, Graham B, Kuski K, Gabriel GG, Mousseau DD (2011) Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro. J Neural Transm 118, 987-995.
80. Steiner H, Fluhrer R, Haass C (2008) Intramembrane prote-olysis by gamma-secretase. J Biol Chem 283, 29627-29631.
81. Wolfe MS (2006) The gamma-secretase complex: Membrane-embedded proteolytic ensemble. Biochemistry 45, 7931-7939. (Pubitemid 43993216)
82. Vetrivel KS, Zhang YW, Xu H, Thinakaran G (2006) Pathological and physiological functions of presenilins. Mol Neurodegen 1, 4.
83. Kim SS, Choi YM, Suh YH (1997) Lack of interactions between amyloid precursor protein and hydrophilic domains of presenilin 1 and 2 using the yeast two hybrid system. J Mol Neurosci 9, 49-54.
84. Hebert SS, Bourdages V, Godin C, Ferland M, Carreau M, Levesque G (2003) Presenilin-1 interacts directly with the beta-site amyloid protein precursor cleaving enzyme (BACE1). Neurobiol Dis 13, 238-245. (Pubitemid 36939188)
85. van Groen T, Kiliaan AJ, Kadish I (2006) Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 23, 653-662. (Pubitemid 44234102)
86. Arai H, Kosaka K, Iizuka R (1984) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 43, 388-393. (Pubitemid 14093566)
87. Curcio CA, Kemper T (1984) Nucleus raphe dorsalis in dementia of the Alzheimer type: Neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 43, 359-368. (Pubitemid 14089416)
88. Ishii T (1966) Distribution of Alzheimer's neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol 6, 181-187.
89. Mann DM, Takeuchi A, Sato S, Cairns NJ, Lantos PL, Rossor MN, Haltia M, Kalimo H, Iwatsubo T (2001) Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as 'cotton wool' plaques. Neuropathol Appl Neurobiol 27, 189-196. (Pubitemid 32678671)
90. Verdile G, Gnjec A, Miklossy J, Fonte J, Veurink G, Bates K, Kakulas B, Mehta PD, Milward EA, Tan N, Lareu R, Lim D, Dharmarajan A, Martins RN (2004) Protein markers for Alzheimer disease in the frontal cortex and cerebellum. Neurology 63, 1385-1392. (Pubitemid 39426269)
91. Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neu-rosci 21, 479-505. (Pubitemid 28150671)
92. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S (1997) Skeletal and CNS defects in presenilin-1-deficient mice. Cell 89, 629-639. (Pubitemid 27511773)
93. Wines-Samuelson M, Handler M, Shen J (2005) Role of presenilin-1 in cortical lamination and survival of Cajal-Retzius neurons. Dev Biol 277, 332-346. (Pubitemid 40022955)
94. Louvi A, Sisodia SS, Grove EA (2004) Presenilin 1 in migration and morphogenesis in the central nervous system. Development 131, 3093-3105. (Pubitemid 39077434)
95. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J (2003) Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 23, 4499-4508. (Pubitemid 36706180)
96. Dori I, Dinopoulos A, Blue ME, Parnavelas JG (1996) Regional differences in the ontogeny of the serotonergic projection to the cerebral cortex. Exp Neurol 138, 1-14. (Pubitemid 26107985)
97. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Muller U, Aguet M, Babinet C, Shih JC et al (1995) Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 268, 1763-1766.
98. Cases O, Vitalis T, Seif I, De Maeyer E, Sotelo C, Gaspar P (1996) Lack of barrels in the somatosensory cortex of monoamine oxidase A-deficient mice: Role of a serotonin excess during the critical period. Neuron 16, 297-307.
99. Cheng A, Scott AL, Ladenheim B, Chen K, Ouyang X, Lathia JD, Mughal M, Cadet JL, Mattson MP, ShihJC (2010) Monoamine oxidases regulate telencephalic neural progenitors in late embryonic and early postnatal development. J Neurosci 30, 10752-10762.
100. Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA (2009) Reex-amining Alzheimer's disease: Evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 18, 447-452.
101. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 110, 1129-1134.
102. Garrick NA, Scheinin M, Chang WH, Linnoila M, Murphy DL (1984) Differential effects of clorgyline on cate-cholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. Biochem Pharmacol 33, 1423-1427. (Pubitemid 14105013)
103. Kitaichi Y, Inoue T, Nakagawa S, Izumi T, Koyama T (2006) Effect of co-administration of subchronic lithium pretreat-ment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats. Eur J Pharmacol 532, 236-245.
104. Westlund KN, Denney RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25, 439-456.
105. Agbayewa MO (1986) Earlier psychiatric morbidity in patients with Alzheimer's disease. J Am Geriatr Soc 34, 561-564. (Pubitemid 16100005)
106. Berger AK, Fratiglioni L, Forsell Y, Winblad B, Backman L (1999) The occurrence of depressive symptoms in the pre-clinical phase of AD: A population-based study. Neurology 53, 1998-2002.
107. Shalat SL, Seltzer B, Pidcock C, Baker EL Jr (1987) Risk factors for Alzheimer's disease: A case-control study. Neurology 37, 1630-1633. (Pubitemid 17163587)
108. Thorpe L, GroulxB (2001) Depressive syndromesindemen-tia. Can J Neurol Sci 28 (Suppl 1), S83-S95.
109. Kasuga K, Ohno T, Ishihara T, Miyashita A, Kuwano R, Onodera O, Nishizawa M, Ikeuchi T (2009) Depression and psychiatric symptoms preceding onset of dementia in a family with early-onset Alzheimer disease with a novel PSEN1 mutation. J Neurol 256, 1351-1353.
110. Tedde A, Forleo P, Nacmias B, Piccini C, Bracco L, Piacentini S, Sorbi S (2000) A presenilin-1 mutation (Leu392Pro) in a familialADkindred with psychiatric symptoms at onset. Neurology 55, 1590-1591.
111. Harvey RJ, Ellison D, Hardy J, Hutton M, Roques PK, Collinge J, Fox NC, Rossor MN (1998) Chromosome 14 familial Alzheimer's disease: The clinical and neuropatho-logical characteristics of a family with a leucine-serine (L250S) substitution at codon 250 of the presenilin 1 gene. J Neurol Neurosurg Psychiatry 64, 44-49. (Pubitemid 28156536)
112. Mejia S, Giraldo M, Pineda D, Ardila A, Lopera F (2003) Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease. Int Psychogeriatr 15, 337-349. (Pubitemid 38186253)
113. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S (2006) Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63, 1209-1216. (Pubitemid 44708079)
114. Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, Ie L, Koo EH (2005) Presenilins mediate phosphatidylinosi-tol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J Biol Chem 280, 31537-31547. (Pubitemid 41291897)
115. Kessing LV, Sondergard L, Forman JL, Andersen PK (2009) Antidepressants and dementia. J Affect Disord 117, 24-29.